SRTD Biotech lands €31.5M seed for next-gen mRNA therapies

What's the deal? SRTD BiotechDealroom has a profile for this one. Try Dealroom →, a German startup based in Jülich near Aachen, has raised a €31.5 million seed round to develop drugs based on a new generation of mRNA technology. France's Mérieux Equity PartnersDealroom has a profile for this one. Try Dealroom → led the round, with the Boehringer Ingelheim Venture FundDealroom has a profile for this one. Try Dealroom → and Lilly VenturesDealroom has a profile for this one. Try Dealroom → also participating.

What's the endgame? SRTD aims to direct mRNA specifically at diseased cells. It plans to build programs targeting cancer as well as autoimmune and fibrosis conditions.

Why now? The raise rides a wave of European mRNA investment. In September, clinical-stage Ethris secured €30 million from the EIB and EU for respiratory therapies, and in October Sensible BiotechnologiesDealroom has a profile for this one. Try Dealroom → raised $47 million for its mRNA manufacturing technology.

By the numbers: At €31.5 million, SRTD's seed ranks among the largest of its kind. It sits in the 99.7th percentile of health-sector seed rounds in Germany over the past 48 months, across a sample of 199 deals.

What could go wrong? The funding signals strong investor interest, but it is no proof of clinical efficacy or a near-term breakthrough. SRTD's first candidate is not slated to enter a clinical trial until 2029.

The signal: Investors are backing mRNA startups well before the clinic, betting on platforms that extend the technology beyond vaccines into cancer and chronic disease. SRTD's outsized seed shows how much capital that promise can still command at the earliest stage.

Read more: handelsblatt.com

Image credit: joebeone